Abstracts tagged "bone biology"

Abstract Number: 0107 • ACR Convergence 2020
Effects of Abaloparatide on Modeling and Remodeling Based Bone Formation
David W Dempster¹, Hua Zhou¹, Sudhaker D Rao², Chris Recknor³, Paul D Miller⁴, Benjamin Z Leder⁵, Miriam Annett⁶, Michael S Ominsky⁶ and Bruce H Mitlak⁶, ¹Regional Bone Center, Helen Hayes Hospital, West Haverstraw, NY, West Haverstraw, NY, ²Bone & Mineral Research Laboratory, Henry Ford Health System, Detroit, MI, Detroit, MI, ³United Osteoporosis Centers, Gainesville, GA, Gainesville, GA, ⁴Colorado Center for Bone Research, Lakewood, CO, Lakewood, CO, ⁵Mass General Hospital, Harvard Medical School, Boston, MA, Boston, MA, ⁶Radius Health, Inc., Waltham, MA, Waltham, MA
Background/Purpose: To evaluate abaloparatide-induced changes in the bone formation indices of mineralizing surface (MS), bone formation rate (BFR) and mineral apposition rate (MAR); and to…
Abstract Number: 0110 • ACR Convergence 2020
Does Urate Directly Influence Bone Turnover? Randomized Controlled Trial of Inosine Supplementation
Nicola Dalbeth¹, Anne Horne², Borislav Mihov¹, Tony Merriman³, Gregory Gamble¹, Lisa Stamp⁴ and Ian Reid¹, ¹University of Auckland, Auckland, New Zealand, ²The University of Auckland, Auckland, New Zealand, ³University of Otago, Dunedin, New Zealand, ⁴University of Otago Christchurch, Christchurch, New Zealand
Background/Purpose: Observational studies have reported that serum urate positively correlates with bone mineral density (BMD) and that hyperuricaemia is protective for the development of osteoporosis…
Abstract Number: 0116 • ACR Convergence 2020
The in Vitro 3D Fracture Gap Model: A Tool for Preclinical Testing
Moritz Pfeiffenberger¹, Alexandra Damerau¹, Paula Hoff², Annemarie Lang¹, Frank Buttgereit³ and Timo Gaber¹, ¹Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Rheumatology and Clinical Immunology, Berlin, Germany, ²Endokrinologikum Berlin, Rheumatologie, Berlin, Germany, ³Charité University Medicine, Berlin, Germany
Background/Purpose: Approximately 10% of fractures lead to significant fracture healing disorders. Of note, especially immunosuppressed patients with ongoing inflammation show difficulties in the correct course…
Abstract Number: 1874 • 2019 ACR/ARP Annual Meeting
Extensive Modeling-Based Bone Formation After 2 Months of Romosozumab Treatment: Results from the FRAME Clinical Trial
Erik Eriksen¹, Roland Chapurlat ², Rogely Boyce ³, Jacques Brown ⁴, Stéphane Horlait ⁵, Cesar Libanati ⁶, Yifei Shi ³, Rachel Wagman ³ and Pascale Chavassieux ², ¹Department of Clinical Endocrinology, Oslo University Hospital and Institute of Clinical Medicine Oslo University, Oslo, Norway, ²INSERM UMR 1033, Université de Lyon, Lyon, France, ³Amgen Inc., Thousand Oaks, CA, ⁴CHU de Quebec Research Centre and Laval University, Quebec, QC, Canada, ⁵Amgen Inc., Boulogne Billancourt, France, ⁶UCB Pharma, Brussels, Belgium
Background/Purpose: The bone-forming agent romosozumab (Romo) is a monoclonal antibody that binds to/inhibits sclerostin, leading to increased bone formation and decreased bone resorption. The highest…
Abstract Number: 846 • 2018 ACR/ARHP Annual Meeting
CD14 Deficiency Dampens Osteoclastogenesis and Alters Bone Remodeling in a Murine Model of Osteoarthritis
Cheng Zhou^1,2, Vu Nguyen^2,3, Ryan Smalley², Nisha Sambamurthy^1,2, George R. Dodge^2,4 and Carla Scanzello^1,2, ¹Division of Rheumatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, ²Translational Musculoskeletal Research Center, CMC Veterans Affairs Medical Center, Philadelphia, PA, ³University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, ⁴Department of Orthopaedic Surgery, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
Background/Purpose: Pathogenesis of osteoarthritis (OA) is accompanied by chronic inflammation evidenced by macrophage infiltration into the joint. CD14, is expressed by monocyte/macrophage lineage cells, and…
Abstract Number: 2399 • 2018 ACR/ARHP Annual Meeting
Bone Density, Structure and Strength in Canadian Children and Youth with Juvenile Idiopathic Arthritis: The LEAP Study (Linking Exercise, Activity, and Pathophysiology in Canadian Children with Arthritis)
Ciarán M. Duffy¹, Adam Baxter-Jones², Leanne Ward³, Heather Macdonald⁴, Heather McKay⁴, Marta Erlandson², Adam Huber⁵, Susanne Benseler⁶, Michele Gibbon⁷, Jaime Guzman⁸ and Lori Tucker⁸, ¹Children's Hospital of Eastern Ontario and University of Ottawa, Ottawa, ON, Canada, ²University of Saskatchewan, Saskatoon, SK, Canada, ³Department of Paediatrics, Children's Hospital of Eastern Ontario, Ottawa, ON, Canada, ⁴University of British Columbia, Vancouver, BC, Canada, ⁵IWK Health Centre, Halifax, NS, Canada, ⁶Alberta Children's Hospital, Calgary, AB, Canada, ⁷Children's Hospital of Eastern Ontario, Ottawa, ON, Canada, ⁸BC Children's Hospital, Vancouver, BC, Canada
Bone Density, Structure and Strength in Canadian Children and Youth with Juvenile Idiopathic Arthritis: The LEAP Study (Linking Exercise, Activity, and Pathophysiology in Canadian Children…
Abstract Number: 68 • 2017 ACR/ARHP Annual Meeting
Tankyrase/Wnt Inhibitor Upregulates Osteoclastogenesis and Osteoblastogenesis Via SH3BP2
Shunichi Fujita¹, Tomoyuki Mukai¹, Takafumi Mito¹, Shoko Kodama¹, Akiko Nagasu¹, Mizuho Kittaka², Yasuyoshi Ueki³ and Yoshitaka Morita¹, ¹Department of Rheumatology, Kawasaki Medical School, Kurashiki, Okayama, Japan, ²Department of Oral and Craniofacial Sciences, School of Dentistry, University of Missouri-Kansas City, Missouri-Kansas City, MO, MO, ³Department of Oral and Craniofacial Sciences, School of Dentistry, University of Missouri-Kansas City, Missouri-Kansas City, MO
Background/Purpose: Tankyrase is a poly (ADP-ribose) polymerase that leads to ubiquitination and degradation of target proteins. Since tankyrase inhibitors increase Axin protein, a negative regulator…
Abstract Number: 69 • 2017 ACR/ARHP Annual Meeting
The Effect of Myostatin Inhibition on Bone Loss in Murine Osteoporosis Models
Tomoyuki Mukai¹, Takafumi Mito¹, Shunichi Fujita¹, Shoko Kodama¹, Akiko Nagasu¹, Teruki Sone², Shinichiro Nishimatsu³, Yutaka Ohsawa⁴, Yoshihide Sunada⁴ and Yoshitaka Morita¹, ¹Department of Rheumatology, Kawasaki Medical School, Kurashiki, Okayama, Japan, ²Department of Nuclear Medicine, Kawasaki Medical School, Kurashiki, Okayama, Japan, ³Department of Natural Sciences, Kawasaki Medical School, Kurashiki, Okayama, Japan, ⁴Department of Neurology, Kawasaki Medical School, Kurashiki, Okayama, Japan
Background/Purpose: Myostatin, also called as growth differentiation factor-8 (GDF-8), is a secreted member of TGF-β superfamily. Myostatin is a negative regulator of skeletal muscle mass…
Abstract Number: 652 • 2017 ACR/ARHP Annual Meeting
Investigating the Role of Mechanical Stress in Spondyloarthritis Pathogenesis
Breanna Nguyen¹, Robert Colbert² and Gerlinde Layh-Schmitt¹, ¹National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ²NIAMS/NIH, Bethesda, MD
Background/Purpose: Mechanotransduction is a cell’s ability to translate mechanical stimuli into biochemical signals and has been implicated in signaling pathways involving differentiation and proliferation. Mechanical…
Abstract Number: 1932 • 2017 ACR/ARHP Annual Meeting
A2A Adenosine Receptor (A2AR) Stimulation Modulates NR4A2 Orphan Receptor Expression during Osteoclast Differentiation
Carmen Corciulo¹, Tuere Wilder¹ and Bruce Cronstein², ¹Department of Medicine, Division of Rheumatology, NYU School of Medicine, New York, NY, ²Rheumatology, New York University School of Medicine, Division of Rheumatology, New York, NY
Background/Purpose: Orphan receptors comprise a large number of evolutionarily conserved molecules that have unknown ligands but may have potent biologic effects. Among these receptors are…
Abstract Number: 1936 • 2017 ACR/ARHP Annual Meeting
Bimekizumab Blocks T Cell-Mediated Osteogenic Differentiation of Periosteal Stem Cells: Coupling Pathological Bone Formation to IL-17A and IL-17F Signaling
Mittal Shah^1,2, Ash Maroof¹, Rawiya Al-Hosni², Panagiotis Gikas³, Neil Gozzard¹, Stevan Shaw¹ and Scott Roberts^1,2, ¹UCB Pharma, Slough, United Kingdom, ²University College London, London, United Kingdom, ³The Royal National Orthopaedic Hospital, London, United Kingdom
Background/Purpose: Structural tissue damage, as a result of pathological bone formation, is a major cause of disability in spondyloarthritis (SpA). A paucity of in vitro…
Abstract Number: 1947 • 2017 ACR/ARHP Annual Meeting
Thy1 Is a Positive Regulator of Osteoblast Differentiation and Modulates Bone Homeostasis in Obese Mice
Ananta Paine¹, Collynn Woeller², Nelson Huertas¹, Maria de la Luz Garcia-Hernandez³, Richard Phipps² and Christopher T. Ritchlin⁴, ¹Department of Medicine, Division of Allergy, Immunology and Rheumatology, School of Medicine and Dentistry, University of Rochester, Rochester, New York, USA, Rochester, NY, ²Department of Environmental Medicine, School of Medicine and Dentistry,, Department of Environmental Medicine, School of Medicine and Dentistry, University of Rochester, Rochester, New York, USA, Rochester, NY, ³Department of Medicine,, Division of Allergy, Immunology and Rheumatology, School of Medicine and Dentistry, University of Rochester, Rochester, New York, USA, Rochester, NY, ⁴Division of Allergy, Immunology and Rheumatology, School of Medicine and Dentistry, Division of Allergy, Immunology and Rheumatology, School of Medicine and Dentistry, University of Rochester, Rochester, New York, USA, Rochester, NY
Background/Purpose: Thy1 (CD90) is a glycosylated, glycophosphatidylinositol (GPI)-anchored membrane protein originally identified as a marker for mouse T cells but subsequent reports noted expression on…
Abstract Number: 323 • 2016 ACR/ARHP Annual Meeting
Effect of 10 Years of Denosumab Treatment on Bone Histology and Histomorphometry in the Freedom Extension Study
David W Dempster^1,2, NS Daizadeh³, A Fahrleitner-Pammer⁴, Jens-Erik Beck Jensen⁵, DL Kendler⁶, Ivo Valter⁷, Rachel B Wagman³, Susan Yue³ and Jacques P Brown⁸, ¹Columbia University, New York, NY, ²Helen Hayes Hospital, West Haverstraw, NY, ³Amgen Inc., Thousand Oaks, CA, ⁴Medical University, Graz, Austria, ⁵Hvidovre University Hospital, Hvidovre, Denmark, ⁶University of British Columbia, Vancouver, BC, Canada, ⁷Center for Clinical and Basic Research, Tallinn, Estonia, ⁸Centre Hospitalier de l'Université Laval (CHUL), Quebec City, QC, Canada
Background/Purpose: Denosumab (DMAb) has been associated with low incidence of spine and non-spine, including hip, fractures through 10 years of treatment (Bone ASBMR 2015). Questions…
Abstract Number: 1097 • 2016 ACR/ARHP Annual Meeting
Tankyrase Regulates Osteoclastogenesis Via SH3BP2
Shunichi Fujita, Tomoyuki Mukai, Takafumi Mito, Shoko Kodama, Akiko Nagasu, Hiroyasu Hirano and Yoshitaka Morita, Department of Rheumatology, Kawasaki Medical School, Kurashiki, Okayama, Japan
Background/Purpose: Tankyrase is a poly (ADP-ribose) polymerase that leads to ubiquitination and degradation of target proteins. Axin, a regulatory protein of Wnt/β-catenin signaling, is one…
Abstract Number: 2137 • 2016 ACR/ARHP Annual Meeting
Subchondral Bone Structure and Pain Behaviors in Collagenase Induced Noninflammatory Monoarthritis in Mice
Hollis E. Krug^1,2, Christopher W. Dorman³, Sandra Frizelle³, Peter A. Valen^2,4 and Maren L. Mahowald^1,2, ¹Medicine, University of Minnesota Medical School, Minneapolis, MN, ²Medicine, Minneapolis VA Health Care System, Minneapolis, MN, ³Research, Minneapolis VA Health Care System, Minneapolis, MN, ⁴Division of Rheumatology, University of Minnesota Medical School, Minneapolis, MN
Background/Purpose: Bone histomorphometry can define OA changes in rodents and in Antigen-Induced arthritis in rats. We previously found that pain from inflammatory monoarthritis in mouse…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].